Featuring news, events and industry trends
Kids with Cerebral Palsy (CP) Participate in NIH-Funded Clinical Trial “Bimanual Training & Transcranial Direct Current Stimulation (tDCS) on Hand Function in Children with Hemiplegia”
In a summer camp-like setting from June 25-29, the Friel Lab at Burke Neurological Institute in White Plains hosted kids with cerebral palsy (CP) for the NIH-funded clinical trial “Bimanual Training & Transcranial Direct Current Stimulation (tDCS) on Hand Function in Children with Hemiplegia.” In collaboration with the Center for Cerebral Palsy Research at Teachers College Columbia University, the research team and kids are examining whether transcranial direct current stimulation (tDCS) can boost the efficacy of bimanual training (2 hrs/day for 5 days). Kids and teens with CP used their hands in activities requiring bimanual coordination. Kids practiced functional bimanual goals, such as tying shoes and buttoning shirts, and had cutthroat Connect Four and Battleship competitions.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Completes Acquisition of Sanofi's Stake in Libtayo® (cemiplimab)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), in Tarrytown, recently announced that it has completed the acquisition of Sanofi's stake in Libtayo® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.

In 2015, Regeneron and Sanofi entered into the Immuno-oncology License and Collaboration Agreement whereby the companies split Libtayo's worldwide operating profits equally and co-commercialized Libtayo in the U.S., with Sanofi solely responsible for commercialization outside the U.S. With this closing, Regeneron will now record 100% of global net sales and expenses for Libtayo.
McKesson and HCA Healthcare Announce Plans to Form an Oncology Research Joint Venture to Advance Cancer Care and Increase Access to Oncology Clinical Research
McKesson Corporation, which has a presence in Yonkers, and HCA Healthcare, Inc. (NYSE: HCA) recently announced an agreement to form a joint venture combining McKesson’s US Oncology Research (USOR) and HCA Healthcare’s Sarah Cannon Research Institute (SCRI). USOR is the research arm of McKesson’s The US Oncology Network and draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. SCRI, which is the research arm of Sarah Cannon, HCA Healthcare’s Cancer Institute, offers end-to-end clinical trial site support services with a deep expertise in early-phase oncology research and drug development as well as a specialized contract research organization (CRO).
Westchester County Biosciences Accelerator 2023 Cohort Info Session
Date: July 6
Time: 10:00 AM

Westchester County Biosciences Accelerator 2023 Cohort Info Session
Date: July 13
Time: 12:00 PM

NYC Builds Bio Presents Gateways to the North: From the Bronx to Westchester
Date: July 26
Time: 12:00 PM

MedTech’s Empire State Focus ’22 Series: Westchester/Hudson Valley
Date: July 28
Time: 10:00 AM

NewYorkBIO’s Virtual Manufacturing Summit
Date: August 5
Time: 9:00 AM

Have good news to share from
Westchester’s bioscience ecosystem?

Please let us know.

If you would like to continue receiving this weekly newsletter,
please sign up below. If you would like to contact us directly, click the Contact Us link.